Debbie K Ledezma, PhD

Presented at #SITC25: exciting novel approach in which monocytes are genetically engineered with CARs to recognize and destroy immunosuppressive tumor associated macrophages in breast cancer. Learn more: jitc.bmj.com/content/13/Sup…

So happy to see that ABRCMS is happening this year!! Please share with your students and/or volunteer!

Dear Colleagues and Friends, Come and join us for making creative signs at Bella Vista tomorrow at 10:30 AM. Unite and stand up for science. See you all tomorrow. Donate: buff.ly/9yvl4ec #Stand_up_for_science #UCSD #Postdoc

@globalimmuno @immunospeaker Such an interesting talk! For the low affinity approach, as the target protein clusters, is the avidity of the antibody expected to be higher? How informative would avidity be compared to avidity when your tram designs these engineered antibodies? #globalimmuno

Please ask questions for today's Global Immunotalk by Mark Cragg HERE by replying to this tweet. Don't forget to mention #globalimmuno. Mark will use the account @immunospeaker to answer questions.

Thank you @sitcancer for a great meeting! I presented some of my research supported by my PI @NF_Steinmetz . The Early Career Scientist mentoring session was wonderful! I truly enjoyed the networking opportunities. And lastly, I got to see some friends from PhD! @GW_IBS #SITC24

Today is National First-Generation College Day. To #CelebrateFirstGen, NCI fellows wrote an Inclusivity Minute on how scientific institutions can recognize and support first-generation #STEM scholars at NCI and beyond. go.nih.gov/OezeJyG

@globalimmuno @jkagan1 Great talk to start off today! Since PGPC appears to induce the tissue damage effect that you propose is needed DC activation, could this be a way to optimized radiotherapy/ablative treatments for improve combination treatments? #globalimmuno

Please ask questions for today's Global Immunotalk by Jon Kagan HERE by replying to this tweet. Don't forget to mention #globalimmuno. Jon will use the account @jkagan1 to answer questions.

New Review by @NF_Steinmetz et al discussing how viruses can be designed as tools and carrier vehicles for intratumoural immunotherapy @tnyomle @KevinZhaoNano @JessicaFAO @CBoonie_nanoIR @lsutorus @JudithVarner2 @NANO_UCSD @UCSDJacobs go.nature.com/4ewQYEo

To RSVP and check out the entire program, click here: forms.gle/aeKAC3JhU8h5cP…

In honor of Hispanic Heritage Month, we present The Atlas of Inspiring Hispanic/Latinx Scientists. This resource showcases the scientific excellence of nearly 400 outstanding scientists. #LatinxAtlas #HispanicHeritageMonth fredhutch.org/en/about/about…

Faculty opening!!! Come build your cancer research program with us at the new Virginia Tech Fralin Biomedical Research Institute Cancer Research Center in Washington, DC. fbri.vt.edu/dc Brand new laboratory space in a research-focused institute based five miles from NIH/NCI, FDA, and the White House. careers.pageuppeople.com/968/cw/en-us/j…

Today is the LAST DAY to take advantage of early-bird pricing for the 2024 BMES Annual Meeting! Don't miss out on the best deal of the year—secure your spot now and save big! 💡 👉 Register now: hubs.la/Q02Mzv030 #BMES2024

Please share this opportunity for undergraduate students attending @sitcancer this November or if they are in the Houston area!! They can meet and network with researchers to learn more about research beyond undergraduate studies. And it's free! sitcancer.org/2024/schedule/…

Dynamic landscapes and protective immunity coordinated by influenza-specific lung-resident memory CD8+ T cells revealed by intravital imaging dlvr.it/TByZJQ

I also had the opportunity to present some of my research using plant viral nanoparticles to make cancer vaccines at the National IRACDA conference! Thanks to @SD_IRACDA, @UNC SPIRE, and my mentor @NF_Steinmetz

It was great to hangout as a cohort all together as well as meeting so many other fellows from across the country! Such a great conference with insightful talks in teaching and mentoring 📚

@globalimmuno @HelftJulie Very interesting talk! I learn a lot. For the two macrophages, FOLR2+ and TREM2+, do they respond differently to DAMPS/PAMPS or do you see a difference in their fuction? Further, outside of cancer, does your group observe similarities if it's inflamed, noncancer tissue?

Please ask questions for today's Global Immunotalk by Dr. Julie Helft HERE by replying to this tweet. Don't forget to mention #globalimmuno. Julie will use the account @HelftJulie to answer questions.

@ChiappinelliLab @GWSMHS Congratulations Kate!! Well-deserved!

Granted tenure and promotion to Associate Professor @GWSMHS, effective July 1. Many thanks to my mentors, collaborators, and colleagues, but most of all to the extraordinary Chiappinelli Lab members who worked so hard, together, through challenging times. Onward!

@globalimmuno @thommen_ds Great talk! I was really intrigued by the increase in patient responders when using CD8-IL2 on PTDFs of anti-PD1 non-responders/resistance. Have you seen similar results when engaging CD4, or does it differ significantly?

Please ask questions for today's Global Immunotalk by Dr. Daniela Thommen HERE by replying to this tweet. Don't forget to mention #globalimmuno. Daniela will use the account @thommen_ds to answer questions.

Donate now: UCSD’s Steinmetz Lab is advancing the most innovative cancer immunotherapy approaches toward a phase 1 human trial - click here to learn more and how to contribute. Thank you! @UCSDJacobs @ucsdiem @NANO_UCSD tritongivingday.ucsd.edu/pages/jacobs-s… steinmetzlab.com/donate